In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia’s ChemGenex High On Leukemia Drug After Trial Results

This article was originally published in PharmAsia News

Executive Summary

ChemGenex of Australia said the latest trial results of its omacetaxine drug to treat chronic myeloid leukemia are so promising it expects the medicine to be on the U.S. market by next March. The new results show an 85 percent remission rate for trial participants who are resistant to standard treatments, ChemGenex said. Analysts see the U.S. market for its drug worth $250 million in 2012 alone. CEO Greg Collier said that based on the positive results, the firm already is interviewing for a chief commercial officer to market the drug. (Click here for more

You may also be interested in...

Spin-Out A Neat Solution For Sanofi’s Manufacturing Millstone

Stada Grabs GSK Brands In Key EU Markets

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales in excess of €100m.

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts